Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2Tumor-Agnostic 1Other hematologic neoplasm 1NET 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

Specimen Handling 10Magnetic Resonance Spectroscopy 10lutetium Lu 177 dotatate 8cabozantinib 4Nivolumab 4Cisplatin 4pembrolizumab 3X-Rays 3Ipilimumab 3Everolimus 3Etoposide 3Carboplatin 3olaparib 2gallium Ga 68 dotatate 2fluorodopa F 18 2fludarabine 2aldesleukin 2Phantoms, Imaging 2Lutetium-177 2Lutetium 2Irinotecan 2Fluorodeoxyglucose F18 2Cyclophosphamide 2CTLA-4 Antigen 2trametinib 1tipifarnib 1sodium thiosulfate 1selpercatinib 1repotrectinib 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
peposertib × Endocrine × 30 days × Clear all
NCT04750954 2026-05-13

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡